Mycobacterial infections in solid organ transplantation

Current Opinion in Organ Transplantation

Volumn 12, Issue 6, 2007, Pages 585-590

  Escalante, Patricio ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Diagnosis; Interferon release assay; Mycobacterium; Nontuberculous mycobacterial infection; Transplantation; Tuberculosis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; AMINOSALICYLIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BCG VACCINE; CALCINEURIN INHIBITOR; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSERINE; CYCLOSPORIN; DILTIAZEM; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; MACROLIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OFLOXACIN; PREDNISONE; PROTIONAMIDE; PYRAZINAMIDE; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; RIFAMYCIN DERIVATIVE; STREPTOMYCIN; TACROLIMUS; UNINDEXED DRUG;

BACTERIAL INFECTION; BCG VACCINATION; COMBINATION CHEMOTHERAPY; CROSS REACTION; DRUG ANTAGONISM; DRUG HALF LIFE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FALSE POSITIVE RESULT; FLOW CYTOMETRY; HUMAN; LUNG TRANSPLANTATION; MORBIDITY; MORTALITY; MYCOBACTERIUM ABSCESSUS; ORGAN TRANSPLANTATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURGICAL TECHNIQUE; TUBERCULIN TEST; TUBERCULOSIS;

EID: 36248953622     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3282f13a88     Document Type: Review

References (62)

1. Klote MM, Agodoa LY, Abbott K. Mycobacterium tuberculosis infection incidence in hospitalized renal transplant patients in the United States, 1998-2000. Am J Transplant 2004; 4:1523-1528.
2. Aguado JM, Herrero JA, Gavalda J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 1997; 63:1278-1286.
3. Queipo JA, Broseta E, Santos M, et al. Mycobacterial infection in a series of 1261 renal transplant recipients. Clin Microbiol Infect 2003; 9:518-525.
4. Matuck TA, Brasil P, Alvarenga Mde F, et al. Tuberculosis in renal transplants in Rio de Janeiro. Transplant Proc 2004; 36:905-906.
5. Lui SL, Tang S, Li FK, et al. Tuberculous infection in southern Chinese renal transplant recipients. Clin Transplant 2004; 18:666-671.
6. John GT, Shankar V. Mycobacterial infections in organ transplant recipients. Semin Respir Infect 2002; 17:274-283.
7. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998; 27:1266-1277.
8. Sinnott JT 4th, Emmanuel PJ. Mycobacterial infections in the transplant patient. Semin Respir Infect 1990; 5:65-73.
9. Schulman LL, Scully B, McGregor CC, Austin JH. Pulmonary tuberculosis after lung transplantation. Chest 1997; 111:1459-1462.
10. Ridgeway AL, Warner GS, Phillips P, et al. Transmission of Mycobacterium tuberculosis to recipients of single lung transplants from the same donor. Am J Respir Crit Care Med 1996; 153:1166-1168.
11. Mourad G, Soulillou JP, Chong G, et al. Transmission of Mycobacterium tuberculosis with renal allografts. Nephron 1985; 41:82-85.
12. Peters TG, Reiter CG, Boswell RL. Transmission of tuberculosis by kidney transplantation. Transplantation 1984; 38:514-516.
13. Malone A, McConkey S, Dorman A, et al. Mycobacterium tuberculosis in a renal transplant transmitted from the donor. Ir J Med Sci 2007; 12 July [Epub ahead of print].
14. Winthrop KL, Kubak BM, Pegues DA, et al. Transmission of Mycobacterium tuberculosis via lung transplantation. Am J Transplant 2004; 4:1529-1533.
15. Lattes R, Radisic M, Rial M, et al. Tuberculosis in renal transplant recipients. Transpl Infect Dis 1999; 1:98-104.
16. Benito N, Sued O, Moreno A, et al. Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation 2002; 74:1381-1386.
17. Mercadal L, Foltz V, Isnard-Bagnis C, et al. Tuberculosis after conversion from azathioprine to mycophenolate mofetil in a long-term renal transplant recipient. Transplant Proc 2005; 37:4241-4243.
18. Hernandez-Hernandez E, Alberu J, Gonzalez-Michaca L, et al. Screening for tuberculosis in the study of the living renal donor in a developing country. Transplantation 2006; 81:290-292. This paper is the first to describe that treating living renal donors with positive TST with isoniazid made no difference in the risk of transmission of TB to recipients in an area of medium-high incidence of TB. A normal chest radiograph, excretory urogram (or contrast CT) and negative urinalysis test, excluded TB transmission to recipients of kidney transplants. This study used a retrospective cohort approach to compare treatment outcomes.
19. Nagai S, Fujimoto Y, Taira K, et al. Liver transplantation without isoniazid prophylaxis for recipients with a history of tuberculosis. Clin Transplant 2007; 21:229-234. This retrospective study described six patients with prior remote history of TB and stable fibrotic chest radiograph findings who underwent liver transplantation without subsequent evidence of TB reactivation. Prior treatment regimes were not known in four of the patients. Even though the patients were followed for 12-84 months posttransplantation, the study sample size was small and potential biases preclude generalization of the results.
20. John GT, Shankar V, Abraham AM, et al. Risk factors for posttransplant tuberculosis. Kidney Int 2001; 60:1148-1153.
21. Poduval RD, Hammes MD. Tuberculosis screening in dialysis patients: is the tuberculin test effective? Clin Nephrol 2003; 59:436-440.
22. Sester M, Sester U, Clauer P, et al. Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in hemodialysis patients. Kidney Int 2004; 65:1826-1834.
23. Shankar MS, Aravindan AN, Sohal PM, et al. The prevalence of tuberculin sensitivity and anergy in chronic renal failure in an endemic area: tuberculin test and the risk of posttransplant tuberculosis. Nephrol Dial Transplant 2005; 20:2720-2724.
24. Sester U, Junker H, Hodapp T, et al. Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrol Dial Transplant 2006; 21:3258-3268. This is a provocative paper that describes a novel test to diagnose accurately LTBI using a rapid quantitative flow-cytometric approach to compare T-cell response to both PPD and the specific TB antigen ESAT-6. Interestingly, this new laboratory approach requires a small volume of blood sampling and the results of the test were not adversely affected by immunosuppression in transplant recipients. The results also correlated well with the ELISPOT-based IRGA results.
25. Barnes PF. Diagnosing latent tuberculosis infection: turning glitter to gold. Am J Respir Crit Care Med 2004; 170:5-6.
26. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004; 170:59-64.
27. Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003; 361:1168-1173.
28. Richeldi L, Ewer K, Losi M, et al. T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. Am J Respir Crit Care Med 2004; 170:288-295.
29. Ferrara G, Losi M, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006; 367:1328-1334. This report is the first to describe a head-to-head comparison between the two commercially available IGRAs using routine clinical samples. The ELISA-based IGRA yielded more indeterminate results compared with the ELISPOT-based IRGA approach in immunosuppressed patients.
30. Kalra V, Agarwal SK, Khilnani GC, et al. Spectrum of pulmonary infections in renal transplant recipients in the tropics: a single center study. Int Urol Nephrol 2005; 37:551-559.
31. Naqvi R, Akhtar S, Noor H, et al. Efficacy of isoniazid prophylaxis in renal allograft recipients. Transplant Proc 2006; 38:2057-2058. This paper supports other prior publications that documented the efficacy of isoniazid treatment for LTBI in renal transplant patients. The description of this prospectively randomized study, however, was limited and there was no mention of risk reduction measurements.
32. Rubin RH. Management of tuberculosis in the transplant recipient. Am J Transplant 2005; 5:2599-2600.
33. Jahng AW, Tran T, Bui L, Joyner JL. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. Transplantation 2007; 83:1557-1562. This paper adds to the small body of evidence that treatment of LTBI in liver transplant candidates, with either isoniazid daily for 9months or rifampin daily for 4months, is feasible and relatively safe if careful monitoring for adverse effects and liver enzymes is provided. There is controversy on this topic among the experts.
34. Singh N, Wagener MM, Gayowski T. Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. Transplantation 2002; 74:892-895.
35. Schluger LK, Sheiner PA, Jonas M, et al. Isoniazid hepatotoxicity after orthotopic liver transplantation. Mt Sinai J Med 1996; 63:364-369.
36. Chan AC, Lo CM, Ng KK, et al. Implications for management of Mycobacterium tuberculosis infection in adult-to-adult live donor liver transplantation. Liver Int 2007; 27:81-85. This case series adds to the small body of evidence that treatment of active TB in liver transplant candidates, with either rifampin or nonrifampin-based regimens, is feasible and relatively safe if careful monitoring for adverse effects and liver enzymes is provided. There is still controversy among the experts, however, on the best treatment approach for active TB infections in liver transplant patients.
37. Offermann G, Keller F, Molzahn M. Low cyclosporin A blood levels and acute graft rejection in a renal transplant recipient during rifampin treatment. Am J Nephrol 1985; 5:385-387.
38. Hebert MF, Fisher RM, Marsh CL, et al. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999; 39: 91-96.
39. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
40. Chang KC, Leung CC, Yew WW, et al. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 2004; 170:1124-1130.
41. Vachharajani TJ, Oza UG, Phadke AG, Kirpalani AL. Tuberculosis in renal transplant recipients: rifampicin sparing treatment protocol. Int Urol Nephrol 2002-2003; 34:551-553.
42. Lopez-Montes A, Gallego E, Lopez E, et al. Treatment of tuberculosis with rifabutin in a renal transplant recipient. Am J Kidney Dis 2004; 44:e59-e63.
43. Marra F, Cox VC, FitzGerald JM, et al. Successful treatment of multidrugresistant tuberculosis following drug-induced hepatic necrosis requiring liver transplant. Int J Tuberc Lung Dis 2004; 8:905-909.
44. Shitrit D, Bendayan D, Saute M, Kramer MR. Multidrug resistant tuberculosis following lung transplantation: treatment with pulmonary resection. Thorax 2004; 59:79-80.
45. Lee J, Yew WW, Wong CF, et al. Multidrug-resistant tuberculosis in a lung transplant recipient. J Heart Lung Transplant 2003; 22:1168-1173.
46. Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004; 38:1428-1439.
47. Chalermskulrat W, Sood N, Neuringer IP, et al. Nontuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006; 61:507-513. This paper addresses the potential predictors of developing NTM infections in patients with cystic fibrosis after lung transplantation using pretransplant cystic fibrosis controls. Despite the rate of nearly 20% of NTM presence in respiratory cultures in pretransplant candidates, only 3.4%of recipients developed invasiveNTM infections. The presence of M. abscessus predicts invasive forms of NTM following lung transplant. Most NTM infections in SOT were successfully treated.
48. Taylor JL, Palmer SM. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J Heart Lung Transplant 2006; 25:985-988.
49. Fairhurst RM, Kubak BM, Shpiner RB, et al. Mycobacterium abscessus empyema in a lung transplant recipient. J Heart Lung Transplant 2002; 21:391-394.
50. Korres DS, Papagelopoulos PJ, Zahos KA, et al. Multifocal spinal and extra-spinal Mycobacterium chelonae osteomyelitis in a renal transplant recipient. Transpl Infect Dis 2007; 9:62-65.
51. Tomazic J, Pirs M, Matos T, et al. Multiple infections after commercial renal transplantation in India. Nephrol Dial Transplant 2007; 22:972-973.
52. Freudenberger RS, Simafranca SM. Cutaneous infection with rapidly-growing mycobacterial infection following heart transplant: a case report and review of the literature. Transplant Proc 2006; 38:1526-1529.
53. Baisi A, Nosotti M, Chella B, Santambrogio L. Relapsing cutaneous Mycobacterium chelonae infection in a lung transplant patient. Transpl Int 2005; 18:1117-1119.
54. Valerga M, Cugliari M, Cefalo E, Martin M. Mycobacterium avium infection in a renal transplant recipient. Enferm Infecc Microbiol Clin 2007; 25:294-295.
55. Todd JL, Lakey J, Howell D, et al. Portal hypertension and granulomatous liver disease in a lung transplant recipient due to disseminated atypical mycobacterial infection. Am J Transplant 2007; 7:1300-1303.
56. Verbeke F, Vogelaers D, Vanholder R,Lameire N. Disseminated Mycobacterium avium complex infection in a renal transplant patient. Eur J Intern Med 2005; 16:53-55.
57. Assi MA, Berg JC, Marshall WF, et al. Mycobacterium gordonae pulmonary disease associated with a continuous positive airway pressure device. Transpl Infect Dis 2007; 9:249-252.
58. Nurmohamed S, Weenink A, Moeniralam H, et al. Hyperammonemia in generalized Mycobacterium genavense infection after renal transplantation. Am J Transplant 2007; 7:722-723.
59. Thaunat O, Morelon E, Stern M, et al. Mycobacterium xenopi pulmonary infection in two renal transplant recipients under sirolimus therapy. Transpl Infect Dis 2004; 6:179-182.
60. Bishburg E, Zucker MJ, Baran DA, Arroyo LH. Mycobacterium xenopi infection after heart transplantation: an unreported pathogen. Transplant Proc 2004; 36:2834-2836.
61. Chernenko SM, Humar A, Hutcheon M, et al. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant 2006; 25:1447-1455. This paper describes the results of an international survey that addresses the incidence and clinical outcomes of M. abscessus in lung transplant recipients. Infection with this organism is uncommon. Treatment of M. abscessus in lung transplant recipients is challenging but successful outcomes can occur with appropriate antimicrobial and surgical approaches.
62. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J RespirCritCare Med 2007; 175:367-416. This paper includes a comprehensive review of all the pertinent literature, but recommendations for diagnosis and treatment of NTM infections in SOT are lacking.